Last updated: 2026-09-16 11:41:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
MaxCyte, Inc. (MXCT) operates in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector and is listed on NASDAQ. The stock is currently priced at $1.18, with a market capitalisation of $121.27M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.64 to $1.87. This page covers its latest market performance, valuation, price trends and company information.
$121.27M | |
$1.18 | |
$17.44 | |
$0.64 | |
$1.19 | |
207.00 | |
1.05M | |
-- | |
$1.87 | |
$0.64 | |
-- | |
-- |
MaxCyte, Inc. (MXCT) is trading at $1.18 in pre-market trading as of 2026-09-16 11:16:00, down 0.84% ($0.01) from the previous close of $1.19
Pre-market trading shows how investors are pricing MXCT before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, MaxCyte, Inc. (MXCT) moved from $1.28 to $1.18, representing a decline of 7.81% ($0.10).
The stock traded between $1.13 and $1.30 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 369.02 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 43.9%
MXCT is currently trading at $1.18, placing it 43.9% of the way from its 52-week low of $0.64 to its 52-week high of $1.87. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
| Industry | SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH |
| Employees | 91 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of MaxCyte, Inc. (MXCT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.